Eli Lilly and Company $LLY Shares Bought by Stratos Wealth Partners LTD.

Stratos Wealth Partners LTD. lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,310 shares of the company’s stock after acquiring an additional 1,183 shares during the period. Stratos Wealth Partners LTD.’s holdings in Eli Lilly and Company were worth $24,653,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Lazard Freres Gestion S.A.S. raised its stake in shares of Eli Lilly and Company by 114.3% in the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock valued at $60,253,000 after acquiring an additional 41,222 shares during the period. Exencial Wealth Advisors LLC boosted its position in Eli Lilly and Company by 189.6% during the 3rd quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock worth $13,283,000 after purchasing an additional 11,396 shares during the period. Rede Wealth LLC acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at $487,000. Central Pacific Bank Trust Division increased its holdings in Eli Lilly and Company by 25.8% in the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock valued at $6,859,000 after purchasing an additional 1,843 shares in the last quarter. Finally, Oak Family Advisors LLC purchased a new position in Eli Lilly and Company in the third quarter valued at about $1,979,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on LLY. HSBC reaffirmed a “hold” rating and issued a $1,070.00 target price on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. CICC Research boosted their price target on Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a research report on Thursday, November 13th. Wall Street Zen cut Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 31st. Rothschild & Co Redburn increased their price objective on shares of Eli Lilly and Company from $775.00 to $830.00 and gave the company a “neutral” rating in a research report on Monday, January 26th. Finally, Loop Capital set a $1,200.00 target price on shares of Eli Lilly and Company in a research report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,217.71.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly agreed to buy Orna Therapeutics for up to $2.4 billion, gaining in‑vivo CAR‑T and circular RNA capabilities that diversify Lilly’s heavy GLP‑1 exposure and bolster long‑term growth prospects. Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion
• Positive Sentiment: Multiple outlets note the Orna deal as strategic entry into next‑generation cell therapy and genetic medicine, which investors view as high‑value pipeline expansion beyond GLP‑1s. LLY Expands Cell Therapy Ambitions With $2.4B Orna Therapeutics Deal
• Positive Sentiment: Fisher Asset Management boosted its Eli Lilly stake by ~153,000 shares, a vote of confidence from a high‑profile investor that can support near‑term buying. Fisher Asset Management Boosts Eli Lilly Stake by 153K Shares
• Positive Sentiment: Lilly advanced two clinical programs: solbinsiran moving forward in high‑risk cholesterol studies and eloralintide entering Phase 3 for obesity — both reinforce future revenue diversification beyond GLP‑1s. Eli Lilly’s Solbinsiran Trial Advances in High-Risk Cholesterol Market
• Positive Sentiment: Deutsche Bank raised its price target on LLY, signaling bullish analyst sentiment and adding to the momentum. Read More
• Neutral Sentiment: Lilly announced an expanded strategic collaboration with Innovent (multi‑billion opportunity) and a partnership with gene‑editing start‑up Seamless — both widen R&D reach but carry usual execution and milestone risk. Eli Lilly Enters $8.5 Billion Strategic Collaboration with Innovent Biologics and Acquires Orna Therapeutics
• Negative Sentiment: Analysts and media continue to flag concentration risk: GLP‑1 drugs still account for a large share of recent revenue, leaving the company exposed if market dynamics shift — valuation (P/E ~45) already prices high growth. Eli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics

Eli Lilly and Company Trading Down 1.9%

Shares of LLY opened at $1,025.06 on Wednesday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The stock has a 50-day moving average price of $1,051.59 and a 200 day moving average price of $902.97. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The company has a market capitalization of $969.08 billion, a P/E ratio of 44.66, a P/E/G ratio of 0.90 and a beta of 0.39.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.48 by $0.06. The company had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a return on equity of 112.50% and a net margin of 31.66%.Eli Lilly and Company’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same period in the previous year, the business earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is currently 30.15%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.